Skip to main content
. 2020 Oct 18;890:173656. doi: 10.1016/j.ejphar.2020.173656

Fig. 4.

Fig. 4

RAS based COVID-19 therapies. [1] ACEIs and ARBs inhibit Ang II/AT1 receptor activation and increase ACE2 expression. [2] Ang (1–7) to counter-balance the deleterious effects of Ang II/AT1 receptor activation. [3] Soluble ACE, block the viral entry.